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Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disorder characterized by progressive eyelid drooping, swallowing difficulties
and proximal limb weakness. OPMD is caused by a small expansion of a short polyalanine tract in the poly (A) binding protein nuclear 1 protein
(PABPN1). The mechanism by which the polyalanine expansion mutation in PABPN1 causes disease is unclear. PABPN1 is a nuclear multi-
functional protein which is involved in pre-mRNA polyadenylation, transcription regulation, and mRNA nucleocytoplasmic transport. The distinct
pathological hallmark of OPMD is the presence of filamentous intranuclear inclusions (INIs) in patient's skeletal muscle cells. The exact
relationship between mutant PABPN1 intranuclear aggregates and pathology is not clear. OPMD is a unique disease sharing common pathogenic
features with other polyalanine disorders, as well as with polyglutamine and dystrophic disorders. This chapter aims to review the rapidly growing
body of knowledge concerning OPMD. First, we outline the background of OPMD. Second, we compare OPMD with other trinucleotide repeat
disorders. Third, we discuss the recent advances in the understanding of the molecular mechanisms underlying OPMD pathogenesis. Finally, we
review recent therapeutic strategies for OPMD.
© 2006 Elsevier B.V. All rights reserved.Keywords: Polyalanine; Oculopharyngeal muscular dystrophy; Intranuclear inclusions; Poly(A) binding protein nuclear 11. Oculopharyngeal muscular dystrophy (OPMD)
background
OPMD (MIM 164300) is an autosomal dominant, adult-
onset disease that usually starts in the fifth or sixth decade of life
[1–3]. The disease is characterized by progressive eyelid
drooping (ptosis), swallowing difficulties (dysphagia), and
proximal limb weakness. OPMD was first described in a
French-Canadian family in 1915 [4], and was recognized as a
distinct disease in 1962 [5]. OPMD has a world-wide
distribution and has been reported in at least 33 countries [6–
16]. The largest OPMD cluster is in the French-Canadian
population, where the estimated prevalence is 1:1000 [17–20],
whilst its highest prevalence is amongst the Bukhara Jews in
Israel (∼1:600). In Europe, the estimated prevalence is 1:100
000 [21].⁎ Corresponding author. Tel.: +1 514 890 8000x24699; fax: +1 514 412 7602.
E-mail address: guy.rouleau@umontreal.ca (G.A. Rouleau).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.10.003Filamentous intranuclear inclusions (INIs) in muscle
fibers of OPMD patients are the pathological hallmark of this
disease [22].
1.1. OPMD symptoms
The symptoms of OPMD, recently reviewed by [23], usually
start insidiously and become manifest in the fifth or sixth
decade, with a slowly progressive course; eventually, beyond
the age of 70, all patients are symptomatic [24]. The main
symptoms are ptosis and dysphagia due to weakness of the
levator palpebrae and pharyngeal muscles. Although other
extraocular muscles may become gradually involved, complete
external ophthalmoplegia is rare and intrinsic eye (ciliary,
sphincter) muscles are not affected [20]. Ptosis is always
bilateral, but may be asymmetrical. Upon progression of ptosis,
patients try to compensate their limitation of the visual field by
contracting the frontal muscle and reclining the head. The
symptoms of dysphagia in OPMD typically are noticed first for
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well. Weakness and atrophy of the tongue can be observed in
the vast majority of patients [25].
Disease progression varies from one individual to another.
Complications include choking, regurgitation, aspiration and
pneumonia [26]. Consecutive aspiration pneumonia, together
with malnutrition or even starvation, are the leading causes of
death in patients with OPMD. However, these events mostly
occur at a later age and life expectancy seems not to be
shortened, although quality of life may be substantially
impaired during the last years of life. The myopathic process
may become manifest with several symptoms other than ptosis
and dysphagia, such as dysarthrophonia, proximal weakness
and facial weakness [27]. A small number of patients in their
late 60s will need a wheelchair [3,25], while others in their 80s
present no significant limb weakness.
OPMD is a myopathy, which affects all voluntary muscles
and appears to spare smooth and cardiac muscles. The muscle
involvement is specific, symmetric and its severity, in
descending order, is: levator palpebrae, tongue, pharynx,
extraocular muscles, iliopsoas, adductor femoris, gluteus
maximus, deltoid and hamstrings [26].
No medical treatment is presently available for OPMD.
Surgical treatments are used to correct the ptosis [28] and
improve swallowing [29,30] in moderately to severely affected
individuals. However, ptosis and dysphagia typically will recur
within five to fifteen years after the surgery.
1.2. OPMD genetics
OPMD is usually inherited as an autosomal dominant trait
with complete penetrance and without gender preference. The
OPMD locus was mapped to chromosome 14q11.2–q13 by
linkage analysis [17], and has been confirmed by others
[11,31,32]. OPMD is caused by expansions of the short
(GCG) trinucleotide repeat in the coding sequence of the poly
(A) binding protein nuclear 1 (PABPN1, also known as
PABP2) gene [33]. The coding sequence of PABPN1
comprises seven exons. Dominant OPMD is caused by an
expansion of a GCG trinucleotide repeat in the first exon [33].
The normal PABPN1 gene has a (GCG)6 repeat encoding a
polyalanine (polyA) stretch at the 5′ end, while in OPMD
patients this repeat is expanded to (GCG)8–13. Due to the
presence of a GCA GCA GCA GCG coding sequence
adjacent to the (GCG)6 repeat, the wild-type PABPN1 protein
has a 10 A stretch, whereas the mutated PABPN1 in dominant
OPMD has 12 to 17 alanines in the N-terminal domain [33].
Interestingly, homozygosity for a (GCG)7 allele leads to an
autosomal recessive form of OPMD. The worst OPMD
phenotype has been observed in patients homozygous for an
autosomal dominant mutation in PABPN1 [34].
1.3. Neurological involvement in OPMD
To date OPMD is considered as a primary myopathic
disorder and there is little morphologic evidence for neurogenic
etiology, though the peripheral nervous system (PNS) seems tobe affected in some rare cases [35]. The first of such cases
reportedly presented a severe depletion of myelinated fibers in
endomysial nerve twigs of extraocular, pharyngeal and lingual
muscles pointing to neurogenic changes in these muscles and
suggesting nerve involvement [35]. In accordance with these
pioneering findings, other more recent reports showed PNS
alterations in members of an OPMD family [36].
The existence of a concomitant axonal sensorimotor
neuropathy in OPMD patients has also been reported
[32,35,37–43]; more interestingly, one case showed involve-
ment of the CNS [44]. Nevertheless, it remains unclear whether
the neuropathy is causatively related to OPMD or whether it is a
coincidental disorder in OPMD patients, or simply a process of
ageing.
Recently, more evidence has emerged suggesting neurolo-
gical involvement in OPMD. Boukriche et al. reported the case
of an OPMD patient who developed a severe chronic axonal
neuropathy [45]. Nakashima et al. reported an OPMD patient
with neurogenic features in the electrophysiological and
pathological findings [46]. Recently, analysis of mitotic and
postmitotic tissues in OPMD transgenic animals revealed
ubiquitinated PABPN1-positive INIs in neuronal cells [47].
Similar INIs in postmortem brain sections from an OPMD
patient were also observed. These results indicate that mutant
PABPN1, presumably via the toxic effects of its polyA tract, can
lead to inclusion formation and neurodegeneration in both the
mouse and the human [47]. These findings raise the possibility
that neurogenic changes, as in polyQ diseases, may contribute
to the pathophysiology of OPMD [47].
1.4. OPMD histopathology
The histology of OPMD muscle biopsy specimens shows
some particular changes: (1) small angulated fibres which may
represent an ageing-related concomitant denervation process,
and (2) rimmed vacuoles within the muscle fibres which most
probably derive from an autophagic process (similar vacuoles
are seen in inclusion body myositis) [48]. Electron microscopy
reveals tubulofilamentous inclusions of about 8.5 nm in
diameter within the nuclei of muscle fibres, which correspond
to INIs and seem to be the most specific diagnostic sign of
OPMD, after genetic testing [48]. These inclusions consist of
mutated, aggregated PABPN1 (see below).
Other histological changes are common to many muscular
dystrophies (loss of muscle fibres, abnormal variation in fibre
size, increase in the number of nuclei, expanded interstitial
fibrous and fatty connective tissue). Although probably all
skeletal muscles are affected, the histologic changes are most
pronounced in extraocular, lingual, pharyngeal and diaphrag-
matic muscles in autopsy findings [20].
1.5. Diagnosis of OPMD
To confirm the diagnosis in patients clinically suspected of
having OPMD, molecular genetic testing is performed.
Considering DNA sequencing as the analytical gold standard,
it is estimated that >99% of patients diagnosed with severe,
Fig. 1. Domains in wild-type PABPN1: the structural organization of wild-type
PABPN1 is schematically illustrated.Wild-type PABPN1 consists of the
following domains: a short alanine stretch, a proline-rich region, an α-helical
region, RNA binding domain overlaps with the first oligomerization domain
(OD1), and a nuclear localization signal (NLS), that overlaps with the
second oligomerization domain (OD2). The amino acid sequence of the C-
terminal NLS domain is indicated.
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PABPN1 triplet repeat expansion [23].
Before genetic testing became available, the diagnosis of
OPMD was made on purely clinical grounds. The presence of
slowly progressive ptosis and dysphagia, an onset of symptoms
after age 40, and a positive family history were pathognomonic.
Later on, light and electron microscopy studies of muscle
biopsy specimens provided further diagnostic confirmation by
the presence of rimmed vacuoles within muscle fibres and
OPMD-specific nuclear inclusion bodies. Additionally, electro
(neuro)myographic studies were used to exclude other neuro-
muscular disorders.
1.6. Poly (A) binding protein nuclear 1 (PABPN1): OPMD
gene product
Wild-type PABPN1 is an abundant nuclear protein, with
wide-spread staining in the nucleoplasm [49]. It is mostly
concentrated in discrete nuclear domains called ‘speckles’
(domains within the nucleus that are enriched in splicing
factors, poly(A) RNA, and other components of the mRNA
processing machinery). Wild-type PABPN1 is a well studied
protein [50]. The predicted molecular weight of wild-type
PABPN1 is 32.8 kDa, but the real molecular weight is higher
due to post-translational modifications-closer to 50 kDa [51].
Wild-type PABPN1 is a multi-domain protein of 306 amino
acids [51] that comprises a polyA stretch of 10 consecutive
alanines and a proline-rich region in the acidic N-terminus.
The residues located between positions 125 and 161 are
predicted to form an α-helix structure which is required for the
stimulation of the poly(A) polymerase [52]. The central region
of wild-type PABPN1 also includes a putative ribonucleopro-
tein (RNP)-type RNA binding domain (RBD) (approximately
from Met161 to Thr257 [51]. The basic C-terminal domain of
wild-type PABPN1, which is rich in dimethylated arginine
residues, contains a nuclear localization signal (NLS) (amino
acids 249–306) (Fig. 1) that interacts with transportin (a
nuclear transport receptor) [51,53]. The association of wild-
type PABPN1 and transportin occurs in a Ran GTP-sensitive
manner, suggesting an active transport pathway [53]. Two
potential oligomerization domains (ODs) of PABPN1 were
mapped out [54]. The first, OD1 (aa 155–294), overlaps with
the RNA binding domain, and the second, OD2 (aa 264–306)
overlaps with the NLS, is localized at the C-terminus of
PABPN1 [54] (Fig. 1).
All eukaryotic mRNA molecules are post-transcriptionally
modified at their 3′-ends by addition of a poly(A) tail, which
binds two different proteins: PABPN1 (nuclear), and PABPC
(cytoplasmic). While wild-type PABPN1 stimulates the rapid
and processive polymerization of the poly (A) tail in the nucleus
[55,56], PABPC in the cytoplasm has a role in the initiation of
translation and in the regulation of mRNA decay [57]. Several
studies suggested that PABPC is a shuttling protein, entering the
nucleus and being exported to the cytoplasm in association with
mRNA [58]. Wild-type PABPN1 is also able to perform
nucleocytoplasmic shuttling, as demonstrated by heterokaryon
assays [53,59].Wild-type PABPN1 binds with high affinity to the poly(A)
tail of mRNA and is involved in mRNA polyadenylation [55].
Polyadenylation is a two-step reaction whereby endonucleolytic
cleavage of the nascent mRNA transcript is followed by the
addition of ∼250 adenylate residues to the up-stream cleavage
product [60–62]. Poly(A) tail synthesis is catalyzed by poly(A)
polymerase through interaction with CPSF, the cleavage and
polyadenylation specificity factor. However, this process is
slow and inefficient, and the length of poly(A) tail is poorly
controlled. Adding PABPN1 to this reaction will stimulate
processive poly(A) addition and control the size of the tail to be
∼250 nucleotides in length [55,56,63]. The RNA binding
domain of PABPN1 mediates its specific binding to the poly(A)
tail of mRNA [50]. Poly(A) bound PABPN1 forms both linear
filaments and discrete-sized, compact oligomeric particles in
vitro [64]. Titration and gel retardation assays indicated that 12
adenylate residues are required for high affinity RNA binding
and the packing density on the poly(A) tail is approximately 15
adenylate residues per PABPN1 molecule [50]. However,
PABPN1 tends to form oligomers even in the absence of
mRNA [51].
1.7. Intranuclear inclusions (INIs): OPMD pathological
hallmark
In 1980, Tome and Fardeau studied deltoid muscle biopsies
from OPMD patients by light and electron microscopy and
identified for the first time a unique accumulation of nuclear
filaments in OPMD muscle fibers [22]. Later reports further
confirmed the presence of the intranuclear inclusions in muscle
nuclei [65–70]. Under an electron microscope, OPMD inclu-
sions can be visualized as filaments that have a tubular
appearance with an outer diameter of 8.5 nm, an inner diameter
of 3 nm and a length of ≤0.25 μm. Filamentous intranuclear
inclusions are considered the pathological hallmark of OPMD
[22,48]. The frequency of nuclei in which filament inclusions
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described size are considered the hallmark of OPMD, as they
differ from all other types of inclusions so far described within
nuclei of muscle fibers [71]. This finding can be considered as a
criterion in making the definite diagnosis of OPMD.
Several in vitro OPMD cell culture models have shown that
mutant PABPN1 over-expression is characterized by the
accumulation of nuclear aggregates [54,72,73,74]. The compo-
sition of intranuclear inclusions might reflect the process of INI
formation and contribute to the pathogenesis of OPMD. Mutant
PABPN1 aggregates have been shown to contain mRNA [59]
and various proteins, including heat shock proteins and
components of the ubiquitin–proteasome pathway [72,73].
Recently, we have shown that the promyelocytic leukemia
(PML) protein, a major component of nuclear bodies, strongly
co-localized to intranuclear aggregates of mutant PABPN1 [75].
Some have hypothesized that sequestration into aggregates may
impair the function of these proteins and perturb their down-
stream pathways. However, it is not clear if their presence in
aggregates compromises protein function. In fact, many of the
proteins demonstrated to be in aggregates are upregulated as a
consequence of mutant PABPN1 expression [76]. In addition, it
is possible that interaction may be transient and proteins may be
able to diffuse in and out of mutant PABPN1 aggregates.
OPMD is one of a number of diseases that are associated
with the formation of aggregates in affected tissues. Whether
these aggregates are pathogenic, or the consequence of a
molecular defense mechanism, remains controversial in these
diseases. In the past, some reports provided data suggesting that
mutant PABPN1 nuclear aggregates may promote cell death in
OPMD [54,72]. Despite these observations, the role of mutant
PABPN1 polyA aggregates as the primary causal event remains
ambiguous. A recent report has shown that polyQ aggregates
may have protective effects in Huntington's disease [77]. The
debate is complex as it is difficult to differentiate experimentally
between the effects of large aggregates, oligomeric species and
the dynamic aggregation process itself.
The polyA expansion mutation is not absolutely required for
the aggregation of mutant PABPN1. Wild-type PABPN1 forms
aggregates when transfected into culture cells and expressed at
high levels [54,72,78] and aggregates comprising wild-type
PABPN1 have been observed in oxytocin-producing neurons
from normal rat hypothalamus [79].
Time-lapse experiments performed in an adenoviral OPMD
model have recently indicated that INIs of mutant PABPN1 are
dynamic structures and can disassemble during mitosis [80].
The dynamism of mutant PABPN1 INIs during cell cycle was
corroborated in recent studies [78,79]. Apoptosis was alsoFig. 2. Dynamics of mutant PABPN1 intranuclear aggregates. In vivo time-lapse
containing protein aggregates (KCl-resistant) undergo cell division. Time is indicateobserved in a small proportion of cells that all had INIs [80].
The authors suggest that as OPMD is a late onset disease, this
slow but constant cell death mechanism could be implicated in
OPMD pathology [80]. We have recently generated similar
results in our OPMD cell model (Fig. 2) (unpublished data).
2. OPMD is a trinucleotide repeat disorder
Many human pathologies involve trinucleotide expansions.
Trinucleotide repeat diseases are caused by expansion of
trinucleotide repeats in a gene. They can be classified according
to the amino acid they code for: polyglutamine (polyQ) repeat
diseases, polyalanine (polyA) repeat diseases. OPMD is a very
unique polyalanine disease sharing common features with
other polyQ disorders, as well as with polyA and dystrophic
disorders [81].
PolyQ diseases that are caused by (CAG)n repeat expansions
represent the largest group of trinucleotide repeat diseases.
PolyQ diseases include Huntington's disease (HD), spinobulbar
muscular dystrophy (SBMA), spinocerebellar ataxias (SCA)
types 1,2,3 (or Machado–Joseph disease MJD), 6, 7, 10, and 12
and dentatorubral pallidoluysian (DRPLA) [82]. It is worth
mentioning that the affected proteins in polyQ diseases and
OPMD are widely expressed yet diseases target specific tissues/
cell types.
The disease course and underlying mechanisms in OPMD
appear to be in some ways similar to that seen in polyQ
expansion disorders as protein misfolding and subsequent
aggregation appear to be central to the pathogenesis [73]. Both
OPMD and polyQ diseases are coding expanded triplet diseases
and both are of late onset. Both polyQ and polyA are
hydrophobic amino acids which are able to form β-sheet
structures and induce intracellular protein aggregation. The
most striking difference between OPMD and polyQ diseases is
the repeat length. Short expansions (>2) of the polyA stretch in
wild-type PABPN1 cause OPMD, while much longer expan-
sions of polyQ (>35) are required to cause neurodegenerative
diseases. It is proposed that polyA is more harmful to the cell
than polyQ [83,84]. Another difference is that in OPMD the
pathogenic effects are mostly observed in skeletal muscle cells
as opposed to neuronal tissues in the case of polyQ disorders.
PolyA tract expansions have now been described in several
human diseases. At least 9 disorders are associated with polyA
expansions (Table 1). Examples of PolyA disorders include:
Synpolydactyly [85,86], cleidocranial dysplasia [87], familial
holoprosencephaly [88], hand–foot–genital syndrome [89],
blepharophimosis/ptosis/epicanthus inversus syndrome type II
[90], X-linked mental retardation and epilepsy [91], X-linkedimages of HeLa cells transfected with mutant PABPN1-A17 showing nuclei
d in hours.
Table 1
Description of polyalanine diseases
Disease Symptoms Gene Protein's function Normal polyA
tract size
Expanded polyA
tract size
Protein
aggregates
Affected
cells
Synpolydactyly
(SPD)
Hand/foot malformation
with syndactyly and
polydactyly, brachydactyly
HOXD13 Transcription factor
patterning of dorsal
axis limbs, genitals
15 22–29 Cytoplasmic Skeletal
Hand–foot–genital
syndrome (HFGS)
Hand/foot malformation
with short thumbs/great
toes, abnormal genitalia
HOXA13 Transcription factor
patterning of dorsal
axis limbs, genitals
18 24–26 Cytoplasmic Skeletal
Cleidocranial
dysplasia (CCD)
Skeletal dysplasia open
fontanelles, tooth
abnormalities, with
hypoplastic clavicles,
short stature
RUNX2(CBFA1) Transcription factor
central role in
morphogenesis of
skeleton, osteoblast
differentiation
17 27 Cytoplasmic Skeletal
Congenital central
hypoventilation
syndrome (CCSH)
Loss of ventilary response
and Hirschsprung disease
PHOX2B Transcription factor
development of brain
20 25–29 Nervous
system
Holoprosencephaly
(HPE)
Malformation of midline
structures of the forebrain
and facial cranium
ZIC2 Transcription factor
development
of brain and limbs
15 25 Nervous
system
Blepharophimosis/
ptosis/epicanthus
inversus syndrome
(BPES)
Blepharophimosis, ptosis,
epicanthus inversus
ovarian failure
FOXL2 Helix/forkhead
transcription factor
expressed in developing
eye and ovaries
14 22–24 Nuclear and
Cytoplasmic
Nervous
system
Infantile spasm
syndrome X-linked
(MR)
Mental retardation,
epilepsy, dystonia
ARX Transcription factor role
in development of
cerebral cortex
and axonal guidance
16
12
18–23
20
Nuclear Nervous
system
X-linked mental
retardation with
growth hormone
deficiency
(MR and GH)
Mental retardation, short
stature caused by growth
hormone
deficiency
SOX3 Transcription factor,
neuronal differentiation
in brain and spinal cord
15 26 Cytoplasmic Nervous
system
Oculopharyngeal
muscular dystrophy
(OPMD)
Progressive, late onset,
muscular weakness of
eyelid, pharyngeal
PABPN1 Poly(A)
binding protein
Regulates length of
poly(A) mRNA tails
10
10
12–17
11
Nuclear Muscles
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congenital central hypoventilation syndrome [93] and oculo-
pharyngeal muscular dystrophy [33].
An alanine expansion was first identified as the disease-
causing mutation in synpolydactyly syndrome (SPD) [85,86].
Since, similar mutations have been described in eight additional
disorders. In contrast to polyQ expansions which cause late
onset neurodegenerative diseases, all polyA disorders, except
for OPMD, result in early developmental defects, such as
malformations of the brain, digits and other structures. All the
mutated genes in polyA diseases, except poly(A) binding
protein nuclear 1 (PABPN1) which causes OPMD, code for
transcription factors that play important roles in early develop-
ment [81]. Furthermore, the size of the alanine expansion
leading to a disease phenotype in OPMD is the smallest ever
described in polyA diseases (Table 1).
Another contrast between polyA and polyQ is the mutational
mechanism. Polymerase slippage has long been assumed to be
the mechanism of expansion in polyQ diseases. In contrast,
polyA expansions are thought to arise from unequal allelic
homologous recombination during meiosis and/or mitosis [94].
Expanded polyA are meiotically and mitotically stable, whereas
expanded polyQ tracts tend to be meiotically and mitotically
unstable [82]. PolyQ repeats show both somatic and germlineinstability. PolyA tracts show only a low degree of polymorph-
ism [95].
Recent findings in OPMD, as well as other polyA
diseases, indicate that protein misfolding and aggregation
may be common features shared with other polyQ diseases.
Until last year, among the family of polyA expanded proteins,
mutant PABPN1 was the only member believed to form
intranuclear inclusions (INIs). Recently, it has been shown for
at least 5 other polyA diseases that mutant protein forms
aggregates [96–98]. Recent reviews focused on the details of
polyA diseases [24,81,95,99–102].
3. OPMD recent molecular mechanisms
Different cellular and animal models, including mice and
Drosophila, were generated to study the pathological mechan-
isms underlying OPMD [54,73,103,104,105].
The mechanism by which the polyA expansion mutation in
PABPN1 causes disease is unclear. However, the mutation is
thought to confer a toxic gain-of-function on the protein. Repeat
length appears to correlate with disease severity. Widespread
expression of the human PABPN1 gene in transgeneic mice
yielded polyA length-dependent muscle pathology, including
vacuoles, central nuclei, and numerous dystrophic changes
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associated with INIs formation [103,104].
The role of the oligomerization of PABPN1 in OPMD
pathogenesis was documented [54]. Among the recent models
put forward to better understand OPMD, some hypothesize that
either involvement of the ubiquitin–proteasome pathway (UPP)
[73] or of the cellular RNA metabolism [59] appears to
contribute to the disease. OPMD intranuclear aggregates were
shown to sequester wild-type PABPN1 [59], poly (A) RNA
[59], hnRNP proteins [106], and components of the UPP and
heat shock proteins (HSPs) pathways [59,72,73]. The role of the
nucleus in OPMD pathogenesis has also been recently
investigated [75] and the apoptosis pathway has been implicated
in OPMD pathogenesis [105].
3.1. PolyA-β sheets in OPMD pathogenesis
The biophysical properties of polyA were suggested to play
an important role in the accumulation of mutant PABPN1 in
OPMD muscle nuclei [24].
PolyA stretches have been found in 494 human proteins [95].
Under physiological conditions in vitro, alanine stretches form
β pleated sheet fibrillar macromolecules that are extremely
resistant to chemical denaturation and enzymatic degradation
[107,108]. Above a threshold of 19 alanines, the polypeptide
aggregates and forms intracellular inclusions, leading to cell
death [109]. Interestingly, alanine stretches within proteins do
not exceed 20 alanines in humans making them relatively short
homopolymeric repeats, when compared with polyQ repeats
[101].
PolyA are frequent in eukaryotic cells, and preferentially
found in transcription factors (TFs); 36% of proteins containing
polyA stretches in humans are TFs [95,110]. Alanine tracts have
been regarded as flexible spacer elements located between
functional domains of the protein and therefore essential to
protein conformation, protein–protein interactions and/or DNA
binding [86,110].
Expanded polyQ and polyA protein repeats are thought to
destabilize the native configuration of the mutant protein
resulting in the formation of protein aggregates within the cell.
It appears likely that an increase of alanine repeat length above
12–22 results in misfolding and/or aggregation of the protein
due to biophysical limitations [111].
It seems surprising that extension of the alanine repeat by
two residues in mutant PABPN1 should have such a drastic
effect as causing OPMD. To find out whether alanine repeats
tend to aggregate, Perutz et al. made the peptide D2A10K2
and measured its Circular Dichroism (CD) spectra in solution
as a function of pH [111]. The spectra showed that the peptide
forms α-helices at all pHs, with no sign of aggregation. α-
Helices can adhere to each other by forming coiled coils, but it
is most unlikely that expansion from six to eight alanines would
have this effect. Perutz suggested the following interpretation:
alanine repeats are hydrophobic and would, therefore, occupy
internal positions in the protein. An additional alanine would be
a misfit that lowers the free energy barrier to unfolding of the
protein [111].In a recent protein structural study, wild-type PABPN1 was
shown to slowly form filaments, while mutant PABPN1 formed
filaments more quickly. Structural analysis of the fibrils
indicated antiparallel β-sheets [112].
In another recent study on polyA repeats, Shinchuk et al.,
analyzed the self-assembly of synthetic poly-(L-alanine) pep-
tides containing 3–20 residues. They found that the conforma-
tional transition and structure of polyA assemblies in solution
are not only length-dependent but also are determined by
concentration, temperature, and incubation time. No β-sheet
complex was detected for those peptides characterized by n<8,
where n are number of alanine residues [113]. Unlike the typical
tinctorial properties of amyloid fibrils, polyA fibrils did not
show fluorescence with thioflavin T or apple-green birefrin-
gence with Congo red. Shinchuk et al. postulated that the high
stability of the macromolecular fibrills of an expanded polyA
stretch could form a core β-sheet structure that mediates the
intermolecular association of mutant proteins into fibrillar
inclusions in human pathologies [113].
Two recent reports by Hung and Hall [114,115] investigated
the kinetics simulation of fibril formation of polyA peptides.
Fibril formation appeared to be a conformational conversion
process in which small amorphous aggregates→β-sheets→or-
dered nucleus→ subsequent rapid growth of a small stable fibril
or protofilament [114,115].
We have recently proposed a potential molecular mechanism
for OPMD pathogenesis [21]. The expansion of the polyA
repeat in mutant PABPN1 causes misfolding and exposes the
hydrophobic alanine stretch, which would otherwise be buried
inside the protein in the wild type form. The longer the polyA
stretch is, the more exposed the hydrophobic region is.
3.2. Oligomerization of mutant PABPN1 in OPMD
pathogenesis
Wild-type PABPN1, when bound to poly(A) RNA, forms
both linear filaments and discrete-sized, compact oligomeric
particles in vitro [50]. Oligomerization of wild-type PABPN1 is
mediated via two potential oligomerization domains (ODs), one
in the middle of the protein and the other at the C-terminus [54].
In this study we provided evidence, in cell culture, that
oligomerization of mutant PABPN1-A17 plays an important
role in the formation of INIs and cell death in OPMD.
Inactivating oligomerization of mutant PABPN1-A17 by
deletions in either of the ODs prevented nuclear protein
aggregation and significantly reduced cell death [54]. It should
be noted that ODs do not overlap with the alanine stretch of
PABPN1. These findings suggest that oligomerization of
mutant PABPN1 plays a crucial role in the formation of
OPMD nuclear protein aggregation, while the expanded polyA
stretch is necessary but not sufficient to induce OPMD protein
aggregation.
Both Congo red and doxycycline (anti-amyloid compounds)
have been found to reduce aggregation and cell death in cell
models of OPMD [116]. The parallel protection that Congo red
affords against the cytotoxicity of expanded polyQ [117] and
polyA is consistent with the idea that abnormal protein
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intracellular amyloidoses, irrespective of the primary mutation.
Recent work on a transgenic model of OPMD provided
evidence that doxycycline (anti-amyloid compound) can be
used as a treatment in OPMD, suggesting that this drug is able to
inhibit oligomerization induced by mutant PABPN1 [103].
3.3. Transcription dysregulation in OPMD pathogenesis
The transcription of muscle-specific genes in OPMD may be
compromised. One group suggested that the continuous
remodeling of adult extraocular muscles leading to the
accumulation of defective mRNA as a consequence of mutant
PABPN1 production could be an explanation for selective
craniofacial involvement in OPMD [118].
A recent study has shown that ectopic expression of mutant
PABPN1 in a muscle cell culture model reduced expression of
several muscle-specific proteins including α-actin, muscle
creatine kinase, and two myogenic transcription factors,
myogenin and MyoD [119]. These findings should be
confirmed in OPMD mice models.
Recent reports support wild-type PABPN1's involvement in
transcription. First, wild-type PABPN1 directly interacts with
the Ski-interacting protein (SKIP) [120], a muscle transcription
regulatory protein which, along with MyoD, regulates muscle
cell differentiation [120]. Second, normal PABPN1 associates
with RNA polymerase II during transcription and accompanies
the released transcript to the nuclear pore [121]. Modifications
of these processes by expanded PABPN1 might play an
important role in OPMD.Fig. 3. Both CBP and p300 transcription factors are recruited into protein aggregates
detection on HeLa and C2C12 cells transfected with mutant PABPN1-A17 (green),
immunodetect CBP and p300 (top middle, bottom middle). Merging (yellow) of theWe have also recently found that both transcription factors
CBP and p300 (histone acetyltransferases) are sequestered into
protein aggregates of mutant PABPN1 in OPMD HeLa and
muscle models (Fig. 3), reinforcing the role of transcriptional
dysfunction in OPMD (unpublished data).
3.4. Involvement of ubiquitin–proteasome pathway (UPP) and
molecular chaperones in OPMD pathogenesis
The situation in OPMD appears to have many parallels with
polyQ diseases and more recently with polyA diseases, raising
the possibility that misfolded, aggregate-prone proteins may
perturb similar pathways, irrespective of the nature of the
mutation or protein context.
The appearance of ubiquitinated aggregates implies an
underlying incapacitation of the cellular chaperones and
proteasome machinery, which normally function to prevent
the accumulation of misfolded proteins [73].
INI formation in mutant PABPN1 may result from an
imbalance between protein refolding and aggregation. Different
observations converge to suggest that a gain of function of
PABPN1 may cause the accumulation of nuclear filaments
observed in OPMD [22]. The involvement of the ubiquitin–
proteasome pathway and molecular chaperones in OPMD is
well documented in several studies. First, Calado et al. showed
that OPMD-specific nuclear inclusions in deltoid muscle from
OPMD patients recruit, in addition to wild-type PABPN1,
ubiquitin and subunits of the proteasome [59]. Second, human,
yeast, and chemical chaperones were shown to reduce both
aggregation and cell death in an OPMD cell model withoutof mutant PABPN1-A17 in both OPMD cellular models. Immunocytochemical
48 h post-transfection. CY3 conjugated secondary antibody (red) was used to
two signals (red and green) illustrates co-localization.
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Baker et al. presented evidence that the UPP and molecular
chaperones are part of the cellular response to mutant polyA-
containing PABPN1. Both HSP70 and ubiquitin were shown to
be recruited into INIs of OPMD in cell-based models and
human tissue [73]. The proteasome inhibitor ‘lactacystin’
resulted in an enhancement of both nuclear and perinuclear
protein aggregation that are associated with cellular toxicity
[73]. Ravikumar et al. also demonstrated that epoxomicin
(another proteasome inhibitor) did increase the proportion of
COS-7 cells expressing green fluorescent protein-A19 (GFP-
A19) aggregates [122].
Recent evidence has shown that over expression of heat
shock proteins HSP70 and HSP40 in cells expressing mutant
PABPN1 increases the solubility of the mutant PABPN1
protein, which consequently reduces the formation of INIs
and cell toxicity [73]. Since these HSPs can promote refolding,
solubilization, and degradation of damaged polypeptides, the
loss of this protective response combined with aging in skeletal
muscle might seriously compromise the cell's capacity to cope
with the mutant PABPN1. Recently, microarray analysis of an
adenoviral model of OPMD revealed that HSP70 was
upregulated, suggesting that there is no compromise of
HSP70 expression [76].
3.5. Possible impairment of mRNA transport or processing in
OPMD pathogenesis
To find out whether a loss-of function underlies OPMD,
Calado et al. measured the steady-state poly(A) tail length in
both OPMD and normal myoblasts [59]. Surprisingly, there
were no significant differences between the steady-state poly(A)
tail length in OPMD and normal myoblasts. However, poly(A)
RNA is detected in OPMD inclusions at higher concentrations
than in the rest of the cell. These findings suggest that mRNA
may be trapped in the inclusions. If this is the case, then the
inclusions may interfere with mRNA export and the cellular
traffic of poly(A) RNA. As a result, depending on the relative
transcription and turnover rates of different mRNA species, in
particular those that are specifically expressed in severely
affected muscles, some protein levels may become inadequate
and contribute to cell death [59].
We have recently identified two wild-type PABPN1 inter-
acting proteins, the heterogenous nuclear ribonucleoproteins
(hnRNP) A1 and A/B [106]. These hnRNPs are mRNA binding
proteins that are involved in both mRNA processing and export
from the nucleus to the cytoplasm [123]. Both hnRNP A1 and
A/B can interact (via the C-terminus) with wild-type PABPN1
and they also co-localize with mutant PABPN1 in OPMD INIs
[106]. More recently, mutant PABPN1 nuclear inclusions were
found to sequester other proteins involved in mRNA biogenesis,
such as poly(A) polymerase (PAP) [78]. It has also been
proposed that wild-type PABPN1 plays a role in mRNA export
[53]. The interaction between wild-type PABPN1 and hnRNP
proteins might be required for the packaging of mRNA for the
export process [106]. Together, these observations and a recent
report of OPMD INIs sequestering mRNA [59] suggest thatOPMD INIs may be toxic by acting as “mRNA traps”
interfering with the mRNA nucleocytoplasmic export.
Recent work on an adenoviral OPMD model revealed that
mutant PABPN1 overexpression leads to upregulating of genes
encoding proteins that are sequestered in OPMD nuclear
inclusions [76]. Interestingly, many of the upregulated genes
encode proteins involved in RNA processing, mRNA splicing,
packaging and transport [76].
Recently, it has been shown that the formation of mutant
PABPN1 inclusions requires binding to poly(A) RNA, and
interfering with any of the protein domains required for
stimulation of poly(A) polymerase prevents the formation of
inclusions [78]. Site-directed mutations within the RNA binding
domain (RBD) of mutant PABPN1 led to mutant protein no
longer forming INIs [78].
3.6. The role of RNA binding domain (RBD) of mutant PABPN1
in OPMD pathogenesis
Recently, Simonelig's group has suggested that the RNA-
binding domain is crucial for OPMD associated toxicity [105].
Simonelig's group [105] has created a Drosophila model of
OPMD that recapitulates the features of the human disorder:
progressive muscle degeneration, with muscle defects propor-
tional to the number of alanines in the tract, and formation of
mutant PABPN1 nuclear inclusions. Strikingly, in their Droso-
phila model, the polyA tract was not absolutely required for
muscle degeneration, whereas another domain of PABPN1, the
RNA-binding domain and its function in RNA binding, are
required. The authors suggest that OPMD does not result from
polyA toxicity, but from an intrinsic property of mutant
PABPN1 dependent on the RBD [105]. They also identified
several suppressors of the OPMD phenotype. For example,
molecular chaperone HSP70 and anti-apoptotic protein P35
were efficient suppressors [105]. It is important to mention that
there is an overlap between the RBD and one of the
oligomerization domains (OD1) of wild-type PABPN1 that
have been characterized by our group [54]. The oligomerization
domains of mutant PABPN1 were shown to be relevant in
OPMD associated toxicity in vitro [54]. Thus, the toxicity may
be dependent on aggregation, which is dependent on the same
domains as the RNA binding.
3.7. The role of the nucleus in OPMD pathogenesis
It is becoming increasingly clear that, although the expanded
polyA stretch in mutant PABPN1 is crucial to initiate OPMD
pathogenesis, residues outside the polyA stretch also play
important roles in the disease [75,105]. We have recently also
presented evidence that the nuclear environment is necessary
for mutant PABPN1 inclusion formation and cellular toxicity
[75]. This was achieved by inactivating the mutant PABPN1
nuclear localization signal (NLS) and by generating full-length
mutant PABPN1 fused to a strong nuclear export signal.
Targeting mutant PABPN1 to the cytoplasm resulted in a
significant suppression of both intranuclear aggregate formation
and cellular toxicity, two hallmarks of OPMD [75].
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Recently, a study on OPMD transgenic mice demonstrated
that doxycycline reduces susceptibility of cells to pro-apoptotic
insults [103]. Doxycycline treatment influenced Bax levels, as
this protein permeabilizes mitochondria, leading to cytochrome
c release and subsequent activation of caspases 9 and 3, after
various pro-apoptotic insults [103]. Bax levels were elevated in
the muscle of A17 mice, compared to wild-type littermates, and
Bax levels in OPMD mice were reduced by doxycycline. Anti-
apoptotic protein P35 was also efficient suppressors in OPMD
Drosophila model [105]. Indeed, other strategies that reduce
apoptosis may be effective in OPMD; lithium decreases the
toxicity induced by expression of a polyA expansion (tagged to
GFP) in a Drosophila model, at least partially via activation of
the anti-apoptotic wnt pathway [124].
4. Treatment advances for OPMD
4.1. Trehalose
The disaccharide chemical chaperone trehalose has been
used effectively to alleviate symptoms in a mouse model of
Huntington's disease [125]. Trehalose is thought to elicit its
effect by binding and stabilizing partially folded polyQ proteins
and inhibiting the formation of aggregates. In OPMD cell and
mouse models [126] it was shown that trehalose decreases the
aggregation and toxicity of mutant PABPN1 [126]. Further-
more, treatment of an OPMD mouse model with trehalose
resulted in the attenuation of muscle weakness, decreased
aggregate formation and a reduced number of TUNEL-positive
nuclei in skeletal muscle fibres [126].
4.2. Single-domain intracellular antibody
Verheesen et al., have recently isolated and characterized a
diverse panel of single-domain antibody reagents (VHH),
recognizing different epitopes in PABPN1 [127]. The antibody
reagents specifically detected endogenous PABPN1 in cell
lysates on Western blot and labeled PABPN1 in cultured cells
and muscle sections. When expressed intracellularly as
intrabodies in a cellular model for OPMD, aggregation of
mutant PABPN1 was prevented in a dose-dependent manner
[127]. More importantly yet, these intrabodies could also reduce
the presence of previously existing aggregates [127].
4.3. Induction of HSP70 expression
The reduction of mutant PABPN1 aggregation by chemical
or molecular chaperones (e.g. HSP70, HSP40) correlates with
decreased death in OPMD cell models [72,73].
Recently, Wang et al. tested four pharmacological agents for
their ability to induce HSP70, and reduce mutant PABPN1
aggregation in a HeLa cell culture model [128]. They showed
that exposure to moderate levels of ZnSO4, 8-hydroxyquino-
line, ibuprofen and indomethacin produced a robust stress
response resulting in the induction of HSP70 in HeLa cellsexpressing the mutant PABPN1-A17 as a GFP fusion protein
[128]. A concomitant reduction of cell death in drug-treated
mutant PABPN1 expressing cells was also observed [128]. Zinc
sulfate (ZnSO4) is an essential mineral nutrient. 8-hydroxyqui-
noline is an anti-microbial anti-parasitic agent used to treat
infections in humans. Ibuprofen and indomethacin are well-
known anti-inflammatory drugs.
4.4. Doxycycline (anti-aggregation and anti-apoptotic)
Rubinsztein's group has developed a transgenic mouse
model of OPMD that manifests progressive muscle weakness
accompanied by intranuclear aggregates and TUNEL-stained
nuclei in skeletal muscle fibers [103]. The onset and severity of
these abnormalities were substantially delayed and attenuated
by doxycycline treatment, which may exert its therapeutic effect
by reducing aggregates and by distinct anti-apoptotic properties.
The authors suggest that doxycycline may represent a safe and
feasible therapeutic for OPMD [103].
4.5. Other therapies: myoblast transfer therapy
Using telomere measurements, Mouly et al. have shown that
the proliferative capacity of satellite cells is dramatically
decreased in muscle dystrophies, thus hampering the possibi-
lities of autologous cell therapy [129]. The authors concluded
that autologous cell therapy can be applied to specific targets
when there is a source of satellite cells which is not yet
exhausted. This is the case of OPMD, and patients suffering
from this disease agreed to participate in a clinical trial using
autologous satellite cells isolated from muscles spared by the
disease.
This resulted in a clinical trial for the pharyngeal muscles of
patients suffering from OPMD. The results of this trial will not
be available for 2 years [129].
5. Conclusions
Despite all the advances in OPMD research, there are still
fundamental questions that need to be addressed for better
understanding of the pathophysiology of OPMD: (1) Which is
the toxic form of the mutant protein: soluble or insoluble, or
both? Does aggregation have a causative role in OPMD-
associated cyto-toxicity? Does it have a role in disease
progression, or is this process in some way protective? (2)
Why is the muscle the most affected tissue in OPMD disease?
(3) Is the underlying mechanism of expanded polyA toxicity in
OPMD a loss or gain of function? (4) Are there mainly primary
or parallel mechanisms acting together in OPMD pathogenesis?
Understanding the molecular pathogenic mechanisms under-
lying OPMD will help to identify the appropriate treatments for
this disease.
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